By IDSE News Staff
An interim analysis of the HIV Prevention Trials Network (HPTN) 083 study evaluating the safety and efficacy of investigational, long-acting injectable cabotegravir for HIV prevention found the long-acting injectable effective as pre-exposure prophylaxis (PrEP).